Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?

H&O Which patients with chronic lymphocytic leukemia (CLL) are eligible for treatment with venetoclax? RF Nearly all patients with CLL are eligible for treatment with venetoclax […]

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting

May 29-31, 2020 • Virtual Venetoclax/Obinutuzumab Continues to Demonstrate Superior Efficacy Long-term results from the CLL14 trial continue to show that fixed-duration venetoclax/obinutuzumab (VenG) continues […]

CLL In Focus

Complete Response Linked to Progression-Free Survival in Chronic Lymphocytic Leukemia Progression-free survival (PFS) is longer in patients with chronic lymphocytic leukemia (CLL) who have a complete […]

Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

H&O What is the mechanism of action for venetoclax, and why is it suited for chronic lymphocytic leukemia (CLL)? JS Venetoclax (Venclexta, AbbVie/Genentech) has a […]

Hem/Onc News

First Biosimilar to Pegfilgrastim Approved to Decrease Risk for Infection During Cancer Treatment On June 4, the US Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila, […]

BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]